Intrastromal injection of bevacizumab in patients with corneal neovascularization

• Published in: Arquivos brasileiros de oftalmologia Vol. 75; no. 4; pp. 277 - 279
• Main Authors: Vieira, Ana Carolina Cabreira, Höfling-Lima, Ana Luisa, Gomes, José Álvaro P, Freitas, Denise de, Farah, Michel Eid, Belfort, Jr, Rubens
• Format: Journal Article
• Language: English
• Published: Brazil Conselho Brasileiro de Oftalmologia 01-07-2012
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab; Corneal Neovascularization - drug therapy; Female; Humans; Injections, Intraocular; Male; OPHTHALMOLOGY; Treatment Outcome; Young Adult; Injections, intraocular; Corneal stroma; Antibodies, monoclonal; Neovascularização da córnea; Substância própria; Anticorpos monoclonais; Corneal neovascularization; Injeções intraoculares
• ISSN: 0004-2749; 1678-2925; 1678-2925
• DOI: 10.1590/S0004-27492012000400012

Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization.